Conditioning compositions and methods of use thereof

Abstract

Compositions and methods of treating skin irritation are disclosed where a conditioning composition is applied to the skin of a user. The compositions and methods are useful to prevent, reduce and/or eliminate irritation of the skin subjected to topical treatment.

1 . A topical skin composition for inhibiting skin irritation comprising:
 one or more anesthetic constituents in an effective amount to inhibit the feeling of skin irritation;   one or more analgesic constituents in an effective amount to inhibit the feeling of skin irritation;   one or more cooling constituents in an effective amount to provide a cooling sensation to skin; and   one or more antimicrobial constituents in an effective amount to inhibit microbes on the skin.   
   
   
       2 . A composition as in  claim 1  wherein the one or more analgesic constituents are selected from the group consisting of acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), narcotic drugs, opioid analgesics, drugs used to treat neuropathic pain syndromes and mixtures thereof. 
   
   
       3 . A composition as in  claim 1  wherein the one or more anesthetic constituents is selected from the group consisting of ambucaine, amolanone, amylocaine, benoxinate, betoxycaine, biphenamine, bupivacaine, levo-bupivacaine, butacaine, butamben, butanilicicaine, butethamine, butoxycaine, carticaine, cocaethylene, cyclomethycaine, dibucaine, dimethisoquin, dimethocaine, diperodon, dyclonine, ecgonidine, ecgonine, ethyl aminobenzoate, ethyl chloride, levo-etidocaine, etidocaine, dextro-etidocaine, β-eucaine, euprocin, fenalcomine, fomocaine, hexylcaine, hydroxyprocaine, hydroxytetracaine, isobutyl p-aminobenzoate, leucinocaine mesylate, levoxadrol, meperidine, levo-mepivacaine, mepivacaine, meprylcaine, metabutoxycaine, methyl chloride, myrtecaine, naepaine, octacaine, orthocaine, oxethazaine, parethoxycaine, phenacaine, phenol, a pipecoloxylidide, piperocaine, piridocaine, polidocanol, pramoxine, sameridine, prilocaine, propanocaine, proparacaine, propipocaine, propoxycaine, pseudococaine, pyrrocaine, quinine urea, risocaine, ropivacaine, levo-ropivacaine, salicyl alcohol, tetracaine, tolycaine, trimecaine, veratridine, zolamine, a 2-alkyl-2-alkylamino-2′,6′-acetoxylidide compounds, a glycerol 1,2-bis-aminoalkyl ether compounds, benzisoxazole compounds, O-aminoalkylsalicylate compounds, heterocyclic phenoxyamine compounds, 2-substituted imidazo(1,2-A)pyridine compounds, 3-aryl substituted imidazo(1,2-A)pyridine compounds, polyorganophosphazene compounds, tertiary-alkylamino-lower acyl-xylidide compounds, amidinourea compounds, 3-(5′-adenylate) of a lincomycin compounds, 3-(5′-adenylate) of a clindamycin compounds, N-substituted derivatives of 1-(4′-alkylsulfonylphenyl)-2-amino-1,3-propanediol compounds, tertiary aminoalkoxyphenyl ether compounds, adenosine, adenosine monophosphate, adenosine diphosphate, adenosine triphosphate, lauryl polyglycol ether compounds, 2-(ω-alkylaminoalkyl)-3-(4-substituted-benzylidene)phthalimidine compounds, 2-(ω-dialkylaminoalkyl)-3-(4-substituted-benzylidene)phthalimidine compounds, ,N,N-triethyl-N-alkyl ammonium salts, L-N-n-propylpipecolic acid-2,6-xylidide compounds, polymers comprising repeating units of one or more local anesthetic moieties, N-substituted 4-piperidinecarboxamide compounds, N-substituted 4-phenyl-4-piperidinecarboxamide compounds and combinations thereof. 
   
   
       4 . A composition as in  claim 1  wherein the one or more cooling constituents are selected from the group consisting of menthol, eucalyptus oil, peppermint oil, cyclohexanol, 5-methyl-2-(1-methylethenyl)-, 6-Isopropyl-9-methyl-1,4-dioxaspiro-(4,5)decane-2-methanol, (I)-menthone glycerol ketal (Menthone Glycerin Acetal), 5-methyl-2-(1-methyl ethyl)-cyclohexyl-2-hydroxypropionate, I-menthyl lactate, acid/-menthyl ester (Menthyl Lactate), menthyl pyrrolidone carboxylate (Menthyl PCA) and mixtures thereof. 
   
   
       5 . A composition as in  claim 1  wherein the one or more antimicrobial constituents are selected from the group consisting of benzethonium chloride, chlorhexidine diacetate, p-Chloro-3,5-m-xylenol and combinations thereof. 
   
   
       6 . A composition as in  claim 1  further comprising a solvent. 
   
   
       7 . A composition as in  claim 1  wherein the solvent is selected from the group consisting of short chain alkyl esters, ethers, aldehydes, ketones, alcohols of benzoic acid, benzyl alcohol, salicylic acid, phenol, phathalic acid and combinations thereof. 
   
   
       8 . A composition as in  claim 1  wherein the one or more analgesic constituents are present in an amount of about 0.01% to about 5.0% based upon the total weight of the composition. 
   
   
       9 . A composition as in  claim 1  wherein the one or more anesthetic constituents are present in an amount of about 0.01% to about 5.0% based upon the total weight of the composition. 
   
   
       10 . A composition as in  claim 1  wherein the one or more cooling agents are present in an amount of about 0.01% to about 0.5% based upon the total weight of the composition. 
   
   
       11 . A composition as in  claim 1  wherein the one or more antimicrobial agents are present in an amount of about 0.01% to about 0.5% based upon the total weight of the composition. 
   
   
       12 . A topical skin composition for inhibiting skin irritation comprising a coolant, Chlorhexadine diacetate, Lidocaine, Pramoxime HCL, and a solvent. 
   
   
       13 . A kit comprising:
 a conditioning composition comprising: one or more anesthetic constituents in an effective amount to inhibit the feeling of skin irritation;
 one or more analgesic constituents in an effective amount to inhibit the feeling of skin irritation; 
 one or more cooling constituents in an effective amount to provide a cooling sensation to skin; and 
 one or more antimicrobial constituents in an effective amount to inhibit microbes on the skin; and 
   a corrective composition.   
   
   
       14 . A method of treating skin and reducing skin irritation comprising:
 contacting skin in need thereof with an effective amount of conditioning composition to prevent skin irritation; and   contacting skin in need thereof with a corrective composition, wherein skin is less irritated than if contacted by corrective composition alone.   
   
   
       15 . A method as in  claim 14  wherein the conditioning composition comprises one or more anesthetic constituents in an effective amount to inhibit the feeling of skin irritation;
 one or more analgesic constituents in an effective amount to inhibit the feeling of skin irritation;   one or more cooling constituents in an effective amount to provide a cooling sensation to skin; and   one or more antimicrobial constituents in an effective amount to inhibit microbes on the skin.